Testing CBD for alzheimer disease

Exclusion

• −Contraindications to CBs, e.g. allergies to cannabis and cannabis products, potential clinically important drug-drug interactions (e.g. strong CYP3A4 inducers/inhibitors, anticonvulsants)
• −Change in psychotropic medications less than the duration of 5 half-lives of the medication in question prior to screeningScreeningThe checks done before joining, to see whether a study fits.Read more → (e.g., concomitant antidepressants or atypical antipsychotics) and any changes during study participation
• −Vascular disease, clinically important cerebrovascular disease or current uncontrolled cardiovascular disease (e.g. uncontrolled hypertension, ischemic heart disease, arrhythmia and severe heart failure, cardiovascular accident in the 3 months prior to Screening (V1)), as per investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more → assessment
• −Clinically significant liver disease, as reflected by serum alanine aminotransferase or aspartate aminotransferase \> 2 x upper limit of normal (ULN), or total bilirubin \> 1.5 x ULN; The Investigator may decide to repeat the assessment to confirm criterion prior to screen failing the participant
• −Clinically significant impaired renal function at screening, as per investigator assessment
• −Clinically significant delusions and/or hallucinations (e.g. NPI-NH delusion/hallucinations subscore ≥4 or judgement of QI)
• −Reported use of marijuana or cannabinoid-based medications, products or supplements (botanical or synthetic) within 1 week prior to randomizationRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more →
• −Systolic blood pressure (SBP) \< 90 mmHg or \> 150 mmHg or diastolic blood pressure (DBP) \< 50mmHg or \> 105 mmHg at screening or baselineBaselineYour starting measurements, taken before treatment begins.Read more → (prior to randomization) or a postural drop in SBP ≥ 20 mmHg or DBP ≥ 10 mmHg at screening
• −Currently meeting DSM 5 criteria for Major Depressive Episode Presence, or current substance dependence (excluding caffeine and nicotine) or history of other major psychiatric disorders or neurological conditions (e.g. psychotic disorders, schizophrenia, stroke, epilepsy)
• −Substance-Related Disorders (excluding caffeine and nicotine)